Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.

Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, Belaunzaran-Zamudio PF, Brown TT, Corey K, Landay AL, Avihingsanon A, Sattler FR, Erlandson KM

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1 Feb 2025Cited by 32 (Europe PMC)

PMID39046173PMCIDPMC11848261DOI10.1093/cid/ciae384PepBankPUB-39046173

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In people with HIV and MASLD, 24 weeks of semaglutide decreased psoas muscle volume by 9.3%.
In plain wordsIn people with HIV and fatty liver disease, psoas muscle volume fell by 9.3% after 24 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreasePsoas muscle volume change
Study
n = 46
Outcome group
Body composition · Musculoskeletal
Studied dose
titrated to 1 mg/week by week 4 · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Psoas muscle volume change
−9.3%
week 24
Source sentences
Summary
Psoas muscle volume decreased by 9.3% (95% confidence interval [CI]: -13.4 to -5.2; P < .001)
2 context sentences(design, population, supporting numbers)
Summary · context
This is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD).
Summary · context
Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4).
Report a problemFND-3904617301
02HumanNon-randomized trialEfficacy outcome
In people with HIV and MASLD, psoas muscle fat did not change significantly over 24 weeks of semaglutide.
In plain wordsIn people with HIV and fatty liver disease, muscle fat did not change clearly after 24 weeks of semaglutide.
Peptide
Semaglutide
Outcome
No significant changePsoas muscle fat change
Study
n = 46
Outcome group
Body composition · Musculoskeletal
Studied dose
titrated to 1 mg/week by week 4 · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Psoas muscle fat change
−0.42%
week 24
Source sentences
Summary
but psoas muscle fat did not significantly change (-0.42%; 95% CI: -1.00 to .17; P = .16).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD).
Summary · context
Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4).
Report a problemFND-3904617302
03HumanNon-randomized trialEfficacy outcome
In people with HIV and MASLD, the 10-time chair rise test showed a nonsignificant improvement over 24 weeks of semaglutide.
In plain wordsIn people with HIV and fatty liver disease, chair rise time did not change significantly after 24 weeks of semaglutide.
Peptide
Semaglutide
Outcome
No significant changeChair rise test
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
titrated to 1 mg/week by week 4 · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Chair rise change
1.27 seconds
week 24
Source sentences
Summary
Chair rise and gait speed showed nonsignificant improvements of 1.27 seconds (95% CI: -2.7 to .10) and 0.05 m/sec (95% CI: -.01 to .10), respectively (both P > .07).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD).
Summary · context
Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4).
Report a problemFND-3904617303
04HumanNon-randomized trialEfficacy outcome
In people with HIV and MASLD, 4 m gait speed showed a nonsignificant improvement over 24 weeks of semaglutide.
In plain wordsIn people with HIV and fatty liver disease, walking speed did not change significantly after 24 weeks of semaglutide.
Peptide
Semaglutide
Outcome
No significant changeGait speed
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
titrated to 1 mg/week by week 4 · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Gait speed change
0.05 m/sec
week 24
Source sentences
Summary
Chair rise and gait speed showed nonsignificant improvements of 1.27 seconds (95% CI: -2.7 to .10) and 0.05 m/sec (95% CI: -.01 to .10), respectively (both P > .07).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD).
Summary · context
Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4).
Report a problemFND-3904617304
05HumanNon-randomized trialEfficacy outcome
In people with HIV and MASLD, the prevalence of slow gait speed fell from 63% to 46% over 24 weeks of semaglutide.
In plain wordsIn people with HIV and fatty liver disease, the share with slow walking speed fell from 63% to 46% after 24 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreasePrevalence of slow gait speed
Study
n: not reported in source
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
titrated to 1 mg/week by week 4 · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Slow gait prevalence, baseline
63%
<1 m/sec
Slow gait prevalence, week 24
46%
<1 m/sec
Source sentences
Summary
The prevalence of slow gait speed (<1 m/sec) decreased from 63% to 46% (P = .029).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD).
Summary · context
Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4).
Report a problemFND-3904617305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04216589

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

National Institute of Allergy and Infectious Diseases (NIAID)n = 5119 Feb 2021 to 15 Sept 2023

HIV Infections · Non-Alcoholic Fatty Liver Disease

Trial page ClinicalTrials.govUpdated 1 Oct 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.